News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ranbaxy Laboratories (RANBAXY.BO), Another Bad FDA Report & the Missing Generic Diovan


6/24/2013 8:12:54 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Once again, Ranbaxy Laboratories may be facing a showdown with the FDA. The troubled generic drugmaker, which only recently agreed to pay $500 million to the US Department of Justice to settle criminal and civil charges associated with a long-running manufacturing scandal (see this), recently received a poor inspection report from the FDA for one of its facilities in India.

Help employers find you! Check out all the jobs and post your resume.

Read at Business Standard
Read at Reuters
Read at Pharmalot

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES